EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Similar documents
PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

End of life prescribing guidance

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

Algorithms for Symptom Management. In End of Life Care

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Symptom Management Guidelines for End of Life Care

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Supportive Care. End of Life Phase

Renal Palliative Care Last Days of Life

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Care of the Dying Management in Severe Renal Failure

Care in the Last Days of Life

Syringe driver in Palliative Care

Care of the Dying Management in Severe Renal Failure

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Palliative care for heart failure patients. Susan Addie

SYRINGE DRIVER MEDICATIONS

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

End Stage Liver Disease Regional Audit Casenote Survey

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Implementing the recommendation on medication management and symptom control

MND Just in Case kit Information for GPs

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

This survey aims to look at individual practice and can be completed by any healthcare professional.

Clatterbridge Centre for Oncology

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

Care of dying adults in the last days of life. Improving care at the very end of life.

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

SCHEDULE 2 THE SERVICES

BREATHLESSNESS MANAGEMENT

Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network

BACKGROUND Measuring renal function :

Conservative Management of Uraemia

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

Isle of Wight Syringe Driver Compatibility Guidelines

Palliative Care Impact Survey

Palliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

The last days of life in hospital and at home

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

Using syringe pumps in palliative care

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Coversheet for Network Site Specific Group Agreed Documentation

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

Regional Renal Training

Community Pharmacy Enhanced Service. Just In Case 4 Core Drugs supply. Stock Holding of Palliative Care Medicines

GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE

Syringe Drivers. Back to top

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July Gosport Hospital Report & RUH Assurance

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

BJF Acute Pain Team Formulary Group

A Brief Guide to Symptom Management and End of Life Care for Children During Pandemic Influenza

What s New 2003? What new treatments? What have you discontinued? More information please!

Specialist Palliative Care Audit and Guidelines Group (SPAGG)

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

Eastern Health and Social Services Board Palliative Care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

PALLIATIVE CARE PRESCRIBING

Palliative Care Formulary

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

SHARED CARE GUIDELINE For


Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

Guidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

Title: Improving the patient experience for children with Sickle Cell Disease Author/Responsible Director: Carole Ribbins Director of Nursing

CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC

PALLIATIVE CARE PRESCRIBING

Palliative Prescribing - Pain

Lothian Palliative Care Guidelines POCKET EDITION 2004

patient group direction

Using strong opiods for pain in palliative care

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

Opioids in Palliative Care

Date of Meeting: Ratified Date: 11/03/2010

Palliative care for patients with brain cancer

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )

Training in palliative and end-of-life care: Guidance for trainees (and their trainers) in non-palliative medicine training posts

Ketamine for Pain Control in Palliative care: A Guide for Patients

CONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259

Transcription:

EAST LANCASHIRE SPECIALIST PALLIATIVE CARE TEAM EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Reviewed and updated August 2009 Next review date August 2011 Approved for use by the East Lancashire Health Economy Drug & Therapeutics Committee. Available online at www.elmmb.nhs.uk, click on Guidelines. Contact: Erin Bolton (End of Life Care Lead NHS East Lancashire) or Wendy Laycock (End of Life Care Lead NHS Blackburn and Darwen and East Lancashire Hospice)

CONTENTS TITLE PAGE EXPLANATORY NOTES 3 PAIN CONTROL USING MORPHINE 5 PAIN CONTROL USING DIAMORPHINE 6 TERMINAL RESTLESSNESS AND AGITATION 7 RESPIRATORY TRACT SECRETIONS 8 NAUSEA AND VOMITING 9 BREATHLESSNESS 10 Original Contributors: Dr Sheelagh Donnelly - Medical Director @ E/L Hospice Pendleside Dr Susan Corkhill - Medical Director @ Pendleside Hospice Kerry Carroll - Macmillan Clinical Nurse Specialist Janet Alston - Clinical Lead East Lancs Hospice Anne Lloyd - Community Matron BwD PCT Fiona Hunt - District Nursing Sister BwD PCT Carmel Wiseman - End of Life Care Project Lead Richard Lee - East Lancashire New Drugs Pharmacist Dr Butterworth - GP BwD PCT Review Date: Aug 09 Reviewed by: Dr Alison Roberts Dr Mark Kitching Dr Susan Corkhill Erin Bolton Eileen Roberts Vince Goodey Consultant in Palliative Medicine, ELHT Consultant in Palliative Medicine. East Lancs Hospice Community Palliative Care Physician End of Life Care Lead, NHS East Lancashire Macmillan CNS Palliative Care (Community) Pharmacy Governance Lead, ELHT 2

East Lancashire Guidelines for the Management of Symptoms in the Last Days of Life Explanatory notes These guidelines- have been prepared to assist in decision making for the prescribing and monitoring of drugs useful in the management of symptoms commonly encountered in the last days of life and are designed for adults have been prepared and approved for use throughout East Lancashire in Primary and Secondary Healthcare settings may be used in patients who have not entered the End of Life Care Pathway must be considered when the End of Life Care Pathway is agreed for a patient Anticipatory prescribing will ensure that, in the last days/hours of life, symptoms can be addressed in a timely manner. Users of this guideline must be aware that- Patients with end-stage cardiac or renal disease may require adjustments to drug doses or the choice of drug. It is beyond the scope of this document to encompass all conditions. Drug doses are a guide only and may be increased or decreased at the discretion of the prescriber. If symptoms persist, or for further advice regarding drug choice or dose please contact the appropriate Specialist Palliative Care Team (details overleaf). Roles and Responsibilities Prescribing Prescribing must only be undertaken by a Doctor or Non-Medical Prescriber in accordance with:- ELHT Medicines Management Policy ELHT/C064 NHS East Lancashire Non-Medical Prescribing Policy/ Policy number 44 ELHT Non-Medical Prescribing Policy ELHT/C098 Drug Administration Drugs must be administered in accordance with:- 3

NHS East Lancashire and NHS Blackburn with Darwen Medicines and Controlled Drugs Policy/ Policy number 59 ELHT Medicines Management Policy ELHT/C64 East Lancashire Specialist Palliative Care (Acute & Community) MS26 SUBCUTANEOUS SYRINGE DRIVER (PALLIATIVE CARE) POLICY AND PROCEDURE Further references Royal Marsden Manual of Clinical Nursing Procedures. Lancashire and South Cumbria Cancer Network Palliative Care Prescribing Guidelines Specialist Palliative Care Team Contact Details ELHT Hospital Specialist Palliative Care Team 01254 732316 Community Specialist Palliative Care Team East Lancashire Macmillan CNS 01254 770070 East Lancashire Hospice Specialist Palliative Care Team Blackburn with Darwen 01254 342810 East Lancashire 24-Hour Specialist Palliative Care Help Line 0773 0639399 4

PAIN CONTROL USING MORPHINE Pain Patient is in pain Patient s pain is controlled Is patient already taking oral morphine? Is patient already taking oral morphine? YES NO YES NO Convert to a Syringe Driver accordingly or seek Specialist Palliative Care advice. doses equating to one sixth of the total dose in the syringe driver. E.g. MORPHINE 30mg s/c via syringe driver will require MORPHINE 5mg s/c hourly prn. Prescribe MORPHINE 5mg s/c hourly prn. If three or more doses required within 4 hours seek medical review. After 24hrs review medication, if two or more doses required prn then consider a syringe driver over 24hrs. Prescribe prn doses equating to one sixth of the total dose in the syringe driver. To convert a patient from oral morphine to a 24hr s/c infusion of MORPHINE divide the total daily dose of morphine by two. E.g. MST 30mg TWICE DAILY orally = MORPHINE 30mg via s/c syringe driver over 24 hours doses equating to one sixth of the total dose in the syringe driver. E.g. MORPHINE 30mg s/c via syringe driver will require MORPHINE 5mg s/c hourly prn. Prescribe MORPHINE 5mg s/c hourly prn. If three or more doses required within 4 hours seek medical review. To convert from other strong opioids, or if symptoms persist contact the Specialist Palliative Care Team or Specialist Palliative Care 24-hour Helpline. WARNING Caution is required in selection of morphine products. Always double check the ampoule strength when preparing doses. Always use the lowest strength ampoules appropriate for the prescribed dose. 5

PAIN CONTROL USING DIAMORPHINE Pain Patient is in pain Patient s pain is controlled Is patient already taking oral morphine? Is patient already taking oral morphine? YES NO YES NO Convert to a Syringe Driver accordingly or seek Specialist Palliative Care advice. Prescribe DIAMORPHINE 2.5mg s/c hourly prn. If three or more doses required within 4 hours seek medical review To convert a patient from oral morphine to a 24hr s/c infusion of DIAMORPHINE divide the total daily dose of morphine by THREE. E.g. MST 30mg BD orally = DIAMORPHINE 20mg via s/c syringe driver over 24 hours. Prescribe DIAMORPHINE 2.5mg s/c hourly prn. If three or more doses required within 4 hours seek medical review doses equating to one sixth of the total dose in the syringe driver. E.g. DIAMORPHINE 20mg s/c via syringe driver will require DIAMORPHINE 2.5mg s/c hourly prn. After 24hrs review medication, if two or more doses required prn then consider a syringe driver over 24hrs. doses equating to one sixth of the total dose in the syringe driver. doses equating to one sixth of the total dose in the syringe driver. E.g., DIAMORPHINE 20mg s/c via syringe driver will require DIAMORPHINE 2.5mg s/c hourly prn. After 24hrs review medication, if two or more doses required prn then consider a syringe driver over 24hrs. doses equating to one sixth of the total dose in the syringe driver. To convert from other strong opioids, or if symptoms persist contact the Specialist Palliative Care Team or Specialist Palliative Care 24-Hour Helpline. WARNING Caution is required in selection of Diamorphine products. Always double check the ampoule strength when preparing doses. Always use the lowest strength ampoules appropriate for the prescribed dose. 6

TERMINAL RESTLESSNESS AND AGITATION Present Absent Prescribe MIDAZOLAM 2.5mg s/c 2-4 hourly prn Prescribe MIDAZOLAM 2.5mg s/c 2-4 hourly prn Review the required medication after 24hrs, if two or more prn doses have been required then consider commencing a syringe driver. Dose should be based on previous 24 hr requirements. If requiring >30mg in 24hr then seek Specialist Palliative Care advice. If two or more doses required in 24 hrs consider commencing a syringe driver over 24 hours. Continue to give 2.5mg s/c 2-4 hourly prn doses accordingly. Prn dose may require titration. Exclude reversible causes and address as appropriate e.g. pain, urinary retention faecal impaction. If symptoms persist contact the Specialist Palliative Care Team or Specialist Palliative Care 24-hour Helpline. WARNING Caution is required in selection of Midazolam products. Always double check the ampoule strength when preparing doses. Caution: Midazolam 10mg/2ml injection strength is reserved only for palliative care use in most clinical settings 7

RESPIRATORY TRACT SECRETIONS Present Absent Prescribe HYOSCINE HYDROBROMIDE 400 micrograms s/c 2-4 hourly prn AND commence syringe driver 1200 micrograms over 24hrs. Prescribe HYOSCINE HYDROBROMIDE 400 micrograms s/c 2-4 hourly prn and administer as soon as secretions apparent. Continue to give prn dose of 400 micrograms to maximum daily dose of 2400 micrograms. If two or more doses of prn HYOSCINE HYDROBROMIDE required then consider a syringe driver commencing at 1200 micrograms s/c over 24hrs. Increase total 24hr dose to 2400 micrograms after 24hrs if symptoms persist. *Note: Do not confuse Hyoscine Hydrobromide with Hyoscine Butylbromide (Buscopan). If symptoms persist contact the Specialist Palliative Care Team or Specialist Palliative Care 24-hour Helpline. 8

NAUSEA AND VOMITING Present Absent Prescribe CYCLIZINE 50mg s/c 8 hourly prn. Prescribe CYCLIZINE 50mg s/c 8 hourly prn. Review after 24 hours if two or more prn doses given then consider a syringe driver with CYCLIZINE 150mg over 24 hours. Consider possible causes for nausea and vomiting and address as appropriate. Cyclizine is not recommended in patients with heart failure. Alternative antiemetics may be prescribed e.g. Haloperidol 1.5mg s/c 4-6 hourly prn (to max 5mg in 24 hours) or up to 5mg via syringe driver. Levomepromazine 6.25mg s/c 4-6 hourly prn (to max 25mg in 24 hours) or up to 25mg via syringe driver. If symptoms persist contact the Specialist Palliative Care Team or the Specialist Palliative Care 24-hour Helpline. 9

EAST LANCASHIRE SPECIALIST PALLIATIVE CARE TEAM BREATHLESSNESS Present Absent General Measures Explanation/Reassurance Fan/Open Window Prescribe Morphine 2.5mg s/c 4 hourly prn Has a reversible cause been identified? YES NO After 24 hours review medication, if two or more doses were required prn, then consider a syringe driver over 24 hours. Treat cause if appropriate Prescribe Morphine 2.5mg s/c 2-4 hourly prn After 24 hours review medication, if two or more doses required prn, then consider a syringe driver over 24 hours. Morphine is useful for management of breathlessness; however prescribing is not necessary if already on strong opioid for pain relief. Prescriptions/authorisations must specify if breathlessness is the indication. If the patient is breathless and anxious consider Midazolam 2.5mg s/c 4 hourly prn, this can also be added to the syringe driver. If symptoms persist contact the Specialist Palliative Care Team or Specialist Palliative Care 24-hour Helpline. WARNING Caution is required in selection of Morphine and Midazolam products. Always double check the ampoule strength when preparing doses. Always use the lowest strength ampoules appropriate for the prescribed dose.